[Fibrinolytic therapy for toxemia of late pregnancy--experimental studies of pregnant rabbits treated with urokinase].
The method for dosing with urokinase (UK) during toxemia of pregnancy, now being studied by us with non- and pregnant rabbits has remained unclarified. The kg/body weight doses determined were 2,500, 5,000, 10,000 and 20,000 in each unit, and the following results were obtained from methods A: a rapid injection, and B: a rapid injection of half the volume followed by drip infusion of the remaining half. The following characteristics of both groups tended to resemble each other: (a) The ELT shortening rate was enhanced with A at doses of 2,500 and 5,000 units/kg, and with B at doses of 10,000 and 20,000 units/kg. (b) alpha 2-antipl., and plg., which tended to decrease with A at doses of 2,500 and 5,000 units/kg, decreased with B more than with A when given 20,000 units/kg. (c) An upward peak of serum FDP was seen in A at 5 minutes and in B at 120 minutes after doses of 10,000 and 20,000 units/kg. Changes with platelet count, PT, APTT and Fbg. were not of significance either both group compared in the non-treated rabbits, irrespective of the dose method employed. Thus, the dose amount of UK during pregnancy nearly equivalent to that in non-pregnancy is seen to be required for enhancement of fibrinolytic activity.
D000818:Animals; D005260:Female; D005338:Fibrin Fibrinogen Degradation Products / Q000032:analysis; D005342:Fibrinolysis; D007263:Infusions, Parenteral; D007275:Injections, Intravenous; D010314:Partial Thromboplastin Time; D011225:Pre-Eclampsia / Q000097:blood / Q000188:drug therapy*; D011247:Pregnancy; D011517:Prothrombin Time; D011817:Rabbits; D013918:Thrombin Time; D014568:Urokinase-Type Plasminogen Activator / Q000008:administration & dosage*
D005338:Fibrin Fibrinogen Degradation Products; D014568:Urokinase-Type Plasminogen Activator